Mieloma Multiple - Mieloma.com

Fuente y mas informacion:
Thu, 21 Jun 2007 14:35:02 -0500 (CDT)
Thu, 14 Jun 2007 12:50:37 -0500 (CDT)
Thu, 7 Jun 2007 13:49:52 -0500 (CDT)
Thu, 31 May 2007 12:44:03 -0500 (CDT)
De:    "MMRF SmartBrief "
http://www.multiplemyeloma.org/

    Leukemia. 2007 Jun 14
    Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation
http://www.ncbi.nlm.nih.gov/sites/e...Pubmed_RVDocSum
Kroger N

    J Support Oncol. 2007 May
    Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma
http://www.ncbi.nlm.nih.gov/sites/e...Pubmed_RVDocSum
Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S

    Clin Lymphoma Myeloma. 2007 Mar
    Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma
http://www.ncbi.nlm.nih.gov/sites/e...Pubmed_RVDocSum
Lipton A, Cook RJ, Coleman RE, Smith MR, Major P, Terpos E, Berenson JR

    Hematology. 2007 Jun
    Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma
http://www.ncbi.nlm.nih.gov/sites/e...Pubmed_RVDocSum
Wang M, Giralt S, Delasalle K, Handy B, Alexanian R

    Am J Hematol. 2007 Jun 1
    Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients
http://www.ncbi.nlm.nih.gov/sites/e...Pubmed_RVDocSum
Zangari M, Esseltine D, Cavallo F, Neuwirth R, Elice F, Burns MJ, Yaccoby S, Richardson P, Sonneveld P, Tricot G

    Curr Opin Oncol. 2007 Jul
    Osteonecrosis of the jaw related to the use of bisphosphonates
http://www.ncbi.nlm.nih.gov/sites/e...Pubmed_RVDocSum
Van den Wyngaert T, Huizing MT, Vermorken JB

    J Cell Biochem. 2007 Jun 1
    Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment
http://www.ncbi.nlm.nih.gov/sites/e...Pubmed_RVDocSum
Mitsiades CS, Mitsiades NS, Richardson PG, Munshi NC, Anderson KC

    Thromb Haemost. 2007 Jun
    Thalidomide and thrombosis. A meta-analysis
http://www.ncbi.nlm.nih.gov/sites/e...Pubmed_RVDocSum
El Accaoui RN, Shamseddeen WA, Taher AT

    Semin Thromb Hemost. 2007 Jun
    Management of thromboembolism in hematologic malignancies
http://www.ncbi.nlm.nih.gov/sites/e...Search=17525901
Chong BH, Lee SH

    Curr Opin Hematol. 2007 Jul
    Genomics and proteomics in multiple myeloma and Waldenstrom macroglobulinemia
http://www.ncbi.nlm.nih.gov/sites/e...Search=17534163
Henry T, Fonseca R

    Blood. 2007 May 29
    The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy
http://www.ncbi.nlm.nih.gov/sites/e...Search=17536013
Yang Y, Macleod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J, Yaccoby S, Shaughnessy JD Jr, Barlogie B, Sanderson RD

    Neth J Med. 2007 May
    Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced
http://www.ncbi.nlm.nih.gov/sites/e...Search=17519513
van Dorp S, Meijer E, van de Donk NW, Dekker AW, Nieuwenhuis K, Minnema MC, Petersen E, Schutgens R, Verdonck LF, Lokhorst HM





____________
Guia de Uso - http://www.mieloma.com/v2/uso-del-foro-vf27.html

Ser feliz no significa que todo sea perfecto, quiere decir que has decidido seguir adelante pese a las dificultades.

Fuente y mas informacion:
Thu, 24 May 2007 12:30:04 -0500 (CDT)
De:    "MMRF SmartBrief "
http://www.multiplemyeloma.org/

    Blood. 2007 May 21
    DKK1 is a widely expressed and potent tumor-associated antigen in multiple myeloma
http://www.ncbi.nlm.nih.gov/sites/e...l=pubmed_docsum
Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD Jr, Epstein J, Kwak LW, Yi Q

    Hematol Oncol. 2007 May 21
    Phase II study of CLAD (cyclophosphamide, liposomal doxorubicin and dexamethasone) in patients with advanced multiple myeloma and historical comparison to CAD (cyclophosphamide, doxorubicin and dexamethasone)
http://www.ncbi.nlm.nih.gov/sites/e...l=pubmed_docsum
Hutter G, Szelenyi H, Schmittel A, Siehl JM, Thiel E, Keilholz U

    J Clin Oncol. 2007 May 21
    American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma
http://www.ncbi.nlm.nih.gov/sites/e...l=pubmed_docsum
Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, Orlowski RZ, Roodman DG, Twilde P, Anderson K

    Haematologica. 2007 Apr
    A dose exploration, phase I/II study of administration of continuous erythropoietin receptor activator once every 3 weeks in anemic patients with multiple myeloma receiving chemotherapy
http://www.ncbi.nlm.nih.gov/sites/e...l=pubmed_docsum
Dmoszynska A, Kloczko J, Rokicka M, Hellmann A, Spicka I, Eid JE





____________
Guia de Uso - http://www.mieloma.com/v2/uso-del-foro-vf27.html

Ser feliz no significa que todo sea perfecto, quiere decir que has decidido seguir adelante pese a las dificultades.